IGF-1 LR3 vs YK-11
A side-by-side research comparison of IGF-1 LR3 and YK-11 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | IGF-1 LR3 | YK-11 |
|---|---|---|
| Full name | Insulin-like Growth Factor-1 Long R3 | YK-11 (Myostatin Inhibitor / SARM) |
| Category | Muscle Growth | Muscle Growth |
| Status | Research compound | Research compound |
| Mechanism | Activates IGF-1R while evading IGFBP sequestration. Triggers PI3K/Akt/mTOR for protein synthesis, satellite cell proliferation, and amino acid uptake into muscle. | Partial androgen receptor agonist that induces follistatin expression, creating dual myostatin inhibition and AR activation. |
| Molecular weight | 9,111 Da | 430.54 Da |
| Half-life | 20-30 hours (vs 15 min native) | ~6-10 hours |
| Bioavailability | High (SubQ/IM) | ~70% oral |
| Typical dose | 20-50 mcg | 5-10 mg |
| Frequency | Daily (post-workout) | Once daily |
| Route | Subcutaneous or intramuscular injection | Oral |
IGF-1 LR3 reported benefits
- Potent anabolic effects
- Hyperplasia (new muscle cells)
- Extended half-life
- Enhanced recovery
- Improved nutrient partitioning
- Satellite cell activation
YK-11 reported benefits
- Dual anabolic mechanism
- Follistatin induction
- Oral convenience
- Muscle hardening
Related comparisons
Research and educational reference only. Not medical advice.